Patients 18 years old and above should receive a risk factor assessment for cardiovascular disease (CVD) at every routine physician visit.
Cardiovascular disease development is closely related to lifestyle characteristics and associated risk factors.
There is an overwhelming scientific evidence that lifestyle modifications and reduction of risk factors can slow the development of CVD both before and after the occurrence of a cardiovascular event.
Very high-risk group refers to patients with documented CVD, by invasive or non-invasive testing, and with presence of risk factors.
High-risk patients are those who have already experienced a cardiovascular event or have very high levels of individual risk factors.
Moderate-risk patients require monitoring of risk profile every 6-12 months.
Low-risk patients may be given conservative management, focusing on lifestyle interventions.
Women diagnosed with nonmetastatic breast cancer who were adherent to cardiovascular disease (CVD) medications pre-diagnosis had a high risk of becoming nonadherent post-cancer treatment, with nonadherence increasing their risk of CV events, according to a poster presented at the recent San Antonio Breast Cancer Symposium (SABCS 2018).
Despite risk factors for cardiovascular disease (CVD) being similar around the world, the burden of CVD is not uniform across nations. Furthermore, CVD-related death in low- to middle-income countries (LMICs) has increased by two-thirds in the last 30 years, and now account for a whopping 80% of global deaths due to CVD.
Gaining weight after quitting smoking may temporarily increase a person’s risk of type 2 diabetes (T2D), a recent US study found, with the risk increasing proportionally with the amount of weight gained. However, quitting smoking is still tied to a reduced risk of death due to cardiovascular disease (CVD).
Low-density lipoprotein cholesterol (LDL-C) levels remained high in many patients with stable or acute coronary heart disease (CHD) in Asia, despite having a very high risk of recurrent cardiovascular (CV) events, indicating that the use of lipid-lowering therapies and lipid monitoring were inadequate.
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
Real-world studies on patients with atrial fibrillation (AF) show that dabigatran is safe with low bleeding and stroke rates when used for long term (over 2 years) or used continuously in patients undergoing cardiovascular (CV) interventions, according to phase II results of the prospective, observational, global registry programme GLORIA-AF* presented at the EHRA 2018 Annual Congress.
Taking marine-derived omega-3 fatty acid (FA) supplements does not appear to protect participants from coronary heart disease (CHD) and major vascular events, regardless of history of vascular disease, lipid levels, statin use, or diabetes, suggests a recent meta-analysis.
Subclinical atherosclerosis, referring to plaque or coronary artery calcification (CAC), is still present in almost half of middle-aged adults free of standard modifiable cardiovascular risk factors (CVRFs) such as hypertension, diabetes, and high LDL cholesterol (LDL-C), reveals the prospective observational PESA* study.
Adding coronary artery calcium (CAC) scores to the traditional Framingham risk score may improve cardiovascular disease (CVD) risk classification in patients with metabolic syndrome or type 2 diabetes (T2D) than using traditional score alone, even in those with diabetes for over 10 years, according to the MESA* study.
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.